Sprim & Tikehau contribute $50mn toward medtech & life science sectors
Date: 2018-03-13   Author: Dhananjay Punekar  Category: #news

Sprim & Tikehau contribute $50mn toward medtech & life science sectors

Tikehau Capital, a private equity firm headquartered in France, has scarcely formed an association with Sprim Ventures, an investor in early stage health solutions. The alliance aims to introduce a USD 50 million early-phase venture capital fund targeting medtech & life sciences firms in Singapore. Industry analysts speculate that the combined entity referred as TKS1 is planning to provide funds to new firms, whose objective is to deliver effective healthcare solutions. The new establishment is also set up to significantly contribute toward the rapid development of therapeutics.

Tikehau Capital handles nearly EUR 13.8 billion of assets as well as asset classes through its asset management division Tikehau IM. Bruno de Pampelonne, Chairperson of Tikehau IM, has stated that with Singapore emerging as an innovation hub, both Sprim and Tikehau have selected medtech & life science firms as their key VC investment destinations. He further added that supportive government policies, a strong R&D ecosystem, and the presence of numerous research institutes & startups have made the country a global hub for carrying out healthcare research activities.

As per reliable reports, TKS1 has announced that it has already funded five firms, namely, ObvioHealth, Travecta Therapeutics, Evid Science, Fibronostics, and Babynostics. TKS1 is likely to focus on initial-stage investments ranging from USD 5,00,000 to USD 5 million across medtech & life science sectors.

The co-founder of Sprim Ventures, Michael Shleifer has announced that through Tikehau Capital support and its own expertise across the healthcare sector, TKS1 will be able to offer exceptional services to the patients & physicians. He asserted that the strategic partnership will assist both the firms in contributing notably towards the growth of the healthcare industry.

Analysts state that this deal forms a part of the lucrative investments witnessed by the medical care sector since the last few years. AltAssets quotes instances of the same, claiming that KKR raised funds worth USD 598 million for its healthcare program while Lilly Asia Ventures closed its fourth healthcare fund round at USD 450 million recently.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Telstra, TPG-Vodafone and Optus lead Australia’s 5G spectrum auctions
Author: Pankaj Singh

The Australian Communications and Media Authority (ACMA) has reportedly announced the outcome of its 5G spectrum auction and one of the largest Australian telco firm, Telstra, has won most of the lots in the 3.6GHz ban...


Window And Door Market Trend & Growth Forecast 2018-2024 By Material - uPVC, Wood, Metal
Author: Rahul Varpe

Apart from uPVC based products, since the last few years, aluminum has gained popularity across windows & doors market. It has been observed that aluminum building components are being extensively used across the r...


Recent Research: Detailed Analysis on Terahertz Imaging Inspection Market Size with Forecast to 2023
Author: Partha Ray

Global Terahertz Imaging Inspection Consumption Market analysis report speaks about the manufacturing process. Global Terahertz Imaging Inspection Consumption market report analyses the market growth, trends, overview & forecast to 2023.The re...